Search Menu

Home
HTB
2009
February
19

19 February 2009

Contents

Antiretrovirals

Increased atazanavir dose recommended when used in combination with efavirenz or Atripla in naive patients

HTB RSS

Early access

US post-authorisation safety data on Pfizer and Moderna vaccines 15 April 2021
US CDC includes HIV as medical criteria for priority to COVID-19 vaccines 15 April 2021
NICE guidelines on management of chronic pain: exercise but not opiods 9 April 2021
Bar opening in the US: 100 guests linked to at least 46 cases of COVID-19 9 April 2021
All early access reports

Current issues

April 2021
March 2021
February 2021
Back issues

Special report

HTB: no. 3 – plus HIV and COVID-19 (12 March 2021) 12 March 2021

More from HTB

Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage

Home

i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

This site complies with the HONcode standard for trustworthy health information.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links: HIV positive; Advocate; Professional; Donate; Feedback

Advice and information: Q and A; Phoneline; Pocket info; Guides; HIV meds; Glossary

Research and conference reports: HTB; HTB South; Pipeline report

Publications and resources: Publications; Other resources; Translations; Slide sets; Order and subscribe

News and updates: News; Blogs

Advocates' network: UK-CAB; Training manual

i-Base: About us; Contact; Sitemap; Home

Find us on Facebook